[Disclosure] Samsung Biologics (207940) Reports Q1 2026 Operating Profit of KRW 580.7B, Up 35.0% YoY

Fact Source: Financial Supervisory Service DART / 2026-04-22

Disclosure Type: Earnings Release (Preliminary Consolidated Financial Results)

💡 3-Second Summary

Samsung Biologics announced its preliminary consolidated financial outcomes for Q1 2026, posting revenue of approximately KRW 1.257T and an operating profit of KRW 580.7B, which marks a year-over-year increase of 25.8% and 35.0%, respectively.

📊 1. [Key Disclosure Content & Major Figures Summary]

• Performance Period: January 1, 2026 – March 31, 2026 (Preliminary Q1 2026 figures)
• Key Consolidated Financial Metrics (Unit: KRW):
  • Revenue: KRW 1,257,119,000,000 (KRW 1.257T)
    • Decreased by 2.2% compared to the sequential quarter (Q4 2025)
    • Increased by 25.8% compared to the same period last year (Q1 2025)
  • Operating Profit: KRW 580,753,000,000 (KRW 580.7B)
    • Increased by 9.9% compared to the sequential quarter (Q4 2025)
    • Increased by 35.0% compared to the same period last year (Q1 2025)
  • Profit Before Income Tax: KRW 640,593,000,000 (KRW 640.6B)
    • Increased by 11.5% QoQ / Increased by 45.9% YoY
  • Net Income (Controlling Interests Equivalent): KRW 469,245,000,000 (KRW 469.2B)
    • Increased by 3.6% QoQ / Increased by 41.6% YoY
• Other Investment Considerations:
  • The historical baseline data for Q1 2025 and Q4 2025 utilize financial audit report amounts that do not reflect the discontinued operations income/loss from Samsung Bioepis due to its corporate spin-off. (Discontinued operations income: KRW 44.22B for Q1 2025 / KRW 56.90B for Q4 2025).
  • These preliminary metrics have not undergone a definitive review by independent external auditors and are subject to adjustment.

📈 2. [Expert Insight: What This Disclosure Means for Investors]

This filing provides actual financial metrics directly tied to the company’s real-time operational performance. Both top-line expansion and core profitability gauges advanced substantially compared to the previous year’s matching period, signaling a potential preservation of its baseline corporate fundamental. In particular, the 35.0% year-over-year advancement in operating profit highlights a steady structural pricing or cost-management framework. The filing does not disclose the specific drivers behind these performance fluctuations, such as segment breakdown or unit cost details.

From an analytical standpoint, although sequential revenues eased slightly by 2.2%, net margins and operating income expanded, pointing toward potential efficiency gains. However, market participants should factor in that the comparative baselines (Q1 and Q4 2025) consist of raw audit metrics unadjusted for the Samsung Bioepis discontinued corporate segments. Given that these preliminary outputs are subject to revision pending external validation, confirming consistency with the subsequent formalized quarterly report remains a recommended step.

📝 Editor’s Comment (by K-STOCK Editor)

Samsung Biologics has laid bare its financial indicators for the opening quarter of 2026. While the headline figures show notable year-over-year adjustments with a 25.8% revenue lift and a 35.0% operating income spike, the text remains strictly factual and omits precise drivers like internal facility utilization profiles or manufacturing batch schedules. Furthermore, because the comparative prior-year metrics are derived from historical audit filings that exclude accounting adjustments for the Bioepis corporate restructure, evaluating actual ongoing expansion requires careful alignment with normalized investor relations briefings to eliminate base-effect distortions. Global participants should monitor final audited outcomes for potential revisions.

📢 Disclaimer & Source Information

Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service electronic disclosure system (DART).

Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.